Join Growin Stock Community!

因華4172.TW Overview

TW StockBiotech. & Medical
(No presentation for 4172)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

因華（4172）Overall Performance

因華（4172）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

因華（4172） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

因華（4172）Key Information

因華（4172）Profile

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company's core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents consisting of gadopentetate dimeglumine and gadodiamide; oncology agents comprising Innomustine and Immurin; and Inpheno tablets for rare diseases. In addition, the company provides MUCR system, OralPas, and OralPas Pro technology platform. Its product pipeline comprises D07001, which is in phase I trial for treatment of tumor; C08001, which is in phase lll for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction; D07002, which is in pilot BE trial used as a supplement for phenylketonuria; and C07001, which is in pilot BE trial for the treatment of parkinson's disease; N11001, which is in pilot BE as urology agents; and D0131502 and D0051301 as contrast agents and is in formulation. The company was founded in 1994 and is based in Taipei, Taiwan.

因華（4172）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.65
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
16.37
PB Ratio
3.02
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
34.27%
Net Margin
-174.56%
Revenue Growth (YoY)
31.94%
Profit Growth (YoY)
395.99%
3-Year Revenue Growth
23.75%
3-Year Profit Growth
-17.50%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.65
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
16.37
PB Ratio
3.02
Price-to-FCF
-
Gross Margin
34.27%
Net Margin
-174.56%
Revenue Growth (YoY)
31.94%
Profit Growth (YoY)
395.99%
3-Year Revenue Growth
23.75%
3-Year Profit Growth
-17.50%
default symbol

4172

因華

15.50D

-0.32%

(-0.00)

  • When is 4172's latest earnings report released?

    The most recent financial report for 因華 (4172) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4172's short-term business performance and financial health. For the latest updates on 4172's earnings releases, visit this page regularly.

  • How much cash does 4172 have?

    At the end of the period, 因華 (4172) held Total Cash and Cash Equivalents of 199.06M, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4172 go with three margins increasing?

    In the latest report, 因華 (4172) did not achieve the “three margins increasing” benchmark, with a gross margin of 20.37%%, operating margin of -93.82%%, and net margin of -107.63%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4172's profit trajectory and future growth potential.